Recurrent small cell lung cancer: update.
Small cell lung cancer continues to recur and claim the lives of most of its victims. Thus, management of the patient with recurrent disease remains an active area of research. This review provides an update of clinical research experience over the past decade with relatively new conventional cytotoxins in this setting, such as the topoisomerase I inhibitors and the taxanes. Additionally, novel molecular targeted approaches with specific relevance for small cell lung cancer are discussed.
Glisson
Bonnie S
BS
Department of Thoracic, Head & Neck Medical Oncology, University of Texas M.D. Anderson Cancer, Center, Houston, TX 77030-4009, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000628:therapy; D002986:Clinical Trials as Topic; D000077156:Gefitinib; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D013873:Thionucleotides / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000922:Immunotoxins; D016376:Oligonucleotides, Antisense; D011799:Quinazolines; D013873:Thionucleotides; C408162:oblimersen; D000077156:Gefitinib